Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5932268 | 0.90 | KMT2A (0.34) | KMT2APAX8 | |
| SCHEMBL20055670 | 0.86 | ALDH1A1 (0.37) | TDP1KMT2A | |
| SCHEMBL22920526 | 0.81 | TDP1 (0.39) | TDP1ADRB2PTGS2OPRK1SLC6A3 | |
| SCHEMBL14818706 | 0.81 | ALDH1A1 (0.32) | TDP1 | |
| SCHEMBL23223575 | 0.80 | ADRB2 (0.34) | TDP1ADRB2PTGS2OPRK1SLC6A3 | |
| SCHEMBL20938972 | 0.79 | TDP1 (0.37) | TDP1ADRB2PTGS2OPRK1SLC6A3 | |
| SCHEMBL28950811 | 0.77 | KMT2A (0.36) | KMT2APAX8 | |
| SCHEMBL22057176 | 0.75 | AOC3 (0.42) | KMT2APAX8 | |
| SCHEMBL24043195 | 0.75 | KMT2A (0.36) | KMT2APAX8 | |
| SCHEMBL13741667 | 0.75 | TDP1 (0.33) | TDP1ADRB2PTGS2OPRK1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230013585-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-19 | — | — | US | disclosed |
| US-11186681-B2 | S-Nitrosothiol-mediated hyperbranched polyesters | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2021-11-30 | — | — | US | disclosed |
| US-20200261453-A1 | CRYSTAL FORM OF OREXIN RECEPTOR ANTAGONIST COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2020-08-20 | — | — | US | disclosed |
| US-10392368-B2 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190225747-A1 | S-NITROSOTHIOL-MEDIATED HYPERBRANCHED POLYESTERS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2019-07-25 | — | — | US | disclosed |
| US-20190040043-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040043-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | JAK3, JAK1, JAK2 | TDP1 3099/4885KMT2A 2047/4885PAX8 4264/4885 |
| US-20190225747-A1 | S-NITROSOTHIOL-MEDIATED HYPERBRANCHED POLYESTERS | NOS2, NOS3, NOS1 | TDP1 239/4885KMT2A 2855/4885PAX8 4674/4885 |
| US-10392368-B2 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | JAK3, JAK1, JAK2 | TDP1 3099/4885KMT2A 2047/4885PAX8 4264/4885 |
| US-20200261453-A1 | CRYSTAL FORM OF OREXIN RECEPTOR ANTAGONIST COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF | HCRTR2, HCRTR1, NPY5R | TDP1 4855/4885KMT2A 2990/4885PAX8 1009/4885 |
| US-11186681-B2 | S-Nitrosothiol-mediated hyperbranched polyesters | NOS2, NOS3, NOS1 | TDP1 239/4885KMT2A 2855/4885PAX8 4674/4885 |
| US-20230013585-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | CDK6, HIPK1, DCK | TDP1 1031/4885KMT2A 1111/4885PAX8 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.